Joon Oh Park
Active 2003–2025
- Also published as
- Joon-Oh Park
- 131
- Papers
- 27,486
- Citations
- 76
- h-index
- 124
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine71.7%
- Biochemistry, Genetics and Molecular Biology21.6%
- Immunology and Microbiology2.9%
- Materials Science0.8%
- Computer Science0.7%
- Neuroscience0.7%
- Other1.6%
Topics
- Pancreatic and Hepatic Oncology Research6.9%
- Cancer Immunotherapy and Biomarkers4.9%
- Cancer Genomics and Diagnostics4.4%
- Lung Cancer Treatments and Mutations4.4%
- Gastric Cancer Management and Outcomes3.8%
- Cholangiocarcinoma and Gallbladder Cancer Studies3.6%
- Other72%
Coauthors
- Jeeyun Lee48
- Won Ki Kang46
- Young Suk Park45
- Ho Yeong Lim35
- Se Hoon Park31
- Do‐Youn Oh28
- Seung Tae Kim25
- Kyoung‐Mee Kim19
- Jung Yong Hong17
- Teresa Macarulla16
- Tae Sung Sohn11
- Eric Van Cutsem10
- Keunchil Park10
- Jae Moon Bae9
- Baek‐Yeol Ryoo8
- Jin Seok Heo8
- Min Gew Choi8
- Eileen M. O’Reilly7
- Jin Won Kim7
- Kihyun Kım7
- Sung Kim7
- Talia Golan7
- Changhoon Yoo6
- Chung‐Pin Li6
All papers
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assénat, Eric Assenat, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Authors: Seung Tae Kim, Răzvan Cristescu, Adam J. Bass, Kyoung‐Mee Kim, Justin I. Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mi-Jin Lee, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Min Gew Choi, AmirAli Talasaz, Peter Kang, Jonathan D. Cheng, Andrey Loboda, Jeeyun Lee, Won Ki Kang - Nature Medicine 2018 cited by 1,717
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Authors: Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler - New England Journal of Medicine 2019 cited by 2,213
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Authors: Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, Erkut Borazanci, Brian M. Wolpin, Salomon M. Stemmer, Talia Golan, Ravit Geva, Mitesh J. Borad, Katrina S. Pedersen, Joon Oh Park, Robert A. Ramirez, David Gutiérrez Abad, Jaime Feliú, Andrés Muñoz, Mariano Ponz‐Sarvisé, Amnon Peled, Tzipora M Lustig, Osnat Bohana‐Kashtan, Stephen M. Shaw, Ella Sorani, Marya Chaney, Shaul Kadosh, Abi Vainstein Haras, Daniel D. Von Hoff, Manuel Hidalgo - Nature Medicine 2020 cited by 533
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Authors: Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne - Science 2007 cited by 4,485
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Authors: Eric Van Cutsem, Margaret A. Tempero, Darren Sigal, Do‐Youn Oh, Nicola Fazio, Teresa Macarulla, Erika Hitre, Pascal Hammel, Andrew Hendifar, Susan E. Bates, Chung‐Pin Li, Sunil R. Hingorani, Christelle de la Fouchardière, Anup Kasi, Volker Heinemann, Anthony Maraveyas, Nathan Bahary, Laura Layos, Vaibhav Sahai, Lei Zheng, Jill Lacy, Joon Oh Park, Fabienne Portales, Paul E. Oberstein, Wilson Wu, Dimitrios Chondros, Andrea J. Bullock, on behalf of the HALO 109-301 Investigators - Journal of Clinical Oncology 2020 cited by 446
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Authors: Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, Andrew Dean, Yan‐Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, J.F. Blanc, Richard Hubner, Chang‐Fang Chiu, Gilberto Schwartsmann, Jens T. Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D. Von Hoff, Li‐Tzong Chen, Clarence S. Adoo, T Anderson, Jamil Asselah, Alan A. Azambuja, Carolyn Bampton, Carlos H. Barrios, Tanios Bekaii‐Saab, Bohuslav Melichar, David Chang, Jen‐Shi Chen, Yeu‐Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csőszi, Antonio Cubillo, Linda C. DeMarco, Maike de Wit, Tomislav Dragovich, W. Jeff Edenfield, Luis Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Vincenzo Iaffaioli, Jitka Jakesova, Zsuzsanna Kahán, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, István Láng, Fa-Chyi Lee, Kuan‐Der Lee, Lara Lipton, Wen Wee, László Mangel, Raul Mena, Daniel H. Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gállego, Cooray Prasad, Kun‐Ming Rau, Jean‐Luc Raoul, Donald Richards, Paul J. Ross, Luís Alberto Schlittler, Martin Šmakal, V. Stahalova, Cora N. Sternberg, Thomas Seufferlein, Niall C. Tebbutt, J. Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong - The Lancet 2015 cited by 1,200
- Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Authors: James J. Harding, Jia Fan, Do‐Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui‐Chuan Sun, Teresa Macarulla, Feng Xie, Jean‐Philippe Metges, Jieer Ying, John Bridgewater, Myung Ah Lee, Mohamedtaki Abdulaziz Tejani, Emerson Y. Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip M. Garfin, Shubham Pant, Ghassan K. Abou‐Alfa, J. Adeva Alfonso, Massimo Aglietta, Ari David Baron, Muhammad Shaalan Beg, Paula Carrasco Aguirre, Eric X. Chen, Ying Cheng, Antonio Cubillo Gracián, Laëtitia Dahan, Filippo de Braud, Elisabetta Fenocchio, Olumide Gbolohon, Roopinder Gillmore, Marine Jary, Milind Javle, Yixing Jiang, Jung Hun Kang, Gentry George King, Madappa N. Kundranda, Laura Layos, Daneng Li, Tingbo Liang, Sara Lonardi, Omkar Marathe, Sebastián Mondaca, Andrés J. Muñoz Martín, Joon Oh Park, Roberto Pazo-Cid, Paula Ribera Fernandez, Lorenza Rimassa, Rosa Alonso, Saeed Sadeghi, Aaron J. Scott, Benjamin Tan, David Tougeron, Qiang Yan, Xiaoyu Yin, Haitao Zhao - The Lancet Oncology 2023 cited by 247
- An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study
Authors: Kota Nakamura, Zhongxu Zhu, Roy S, Eunsung Jun, Haiyong Han, Rubén M. Muñoz, Satoshi Nishiwada, Geeta G. Sharma, Derek Cridebring, Frédéric Zenhausern, Seungchan Kim, Denise J. Roe, Sourat Darabi, In Woong Han, Douglas B. Evans, Suguru Yamada, Michael J. Demeure, Carlos Becerra, Scott Celinski, Erkut Borazanci, Susan Tsai, Yasuhiro Kodera, Joon Oh Park, John S. Bolton, Xin Wang, Song Cheol Kim, Daniel D. Von Hoff, Ajay Goel - Gastroenterology 2022 cited by 162
- Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions
Authors: Wei Lin, Pawan Noel, Erkut Borazanci, Jeeyun Lee, Albert Amini, In Woong Han, Jin Seok Heo, Gayle Jameson, Cory Fraser, Margaux Steinbach, Yanghee Woo, Yuman Fong, Derek Cridebring, Daniel D. Von Hoff, Joon Oh Park, Haiyong Han - Genome Medicine 2020 cited by 342
- Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
Authors: Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal - Cancer Discovery 2021 cited by 248
- Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Authors: Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan - Journal of Clinical Oncology 2022 cited by 225
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Authors: Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li‐Tzong Chen, Masayuki Kitano, Choong‐kun Lee, Jin Won Kim, Ming‐Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen‐Shi Chen, Piotr Potemski, Howard A. Burris, Vikas Ostwal, Suebpong Tanasanvimon, Chigusa Morizane, Renata Zaucha, Mairéad G. McNamara, Antonio Avallone, Juan E Cundom, В. В. Бредер, Benjamin Tan, Satoshi Shimizu, David Tougeron, Ludovic Evesque, Mila Petrova, David B. Zhen, Roopinder Gillmore, Vineet Gupta, Farshid Dayyani, Joon Oh Park, Gary L. Buchschacher, Felipe Rey, Hyosung Kim, Julie Wang, Claire Morgan, Nana Rokutanda, Magdalena Żotkiewicz, Arndt Vogel, Juan W. Valle - The Lancet. Gastroenterology & hepatology 2024 cited by 254
- Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Authors: Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo - The Lancet Oncology 2015 cited by 845
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
Authors: Jin‐Young Jang, Youngmin Han, Hongeun Lee, Sun‐Whe Kim, Wooil Kwon, Kyung-Hun Lee, Do‐Youn Oh, Eui Kyu Chie, Jeong Min Lee, Jin Seok Heo, Joon Oh Park, Do Hoon Lim, Seong Hyun Kim, Sang‐Jae Park, Woo Jin Lee, Young Hwan Koh, Joon Seong Park, Dong Sup Yoon, Ik Jae Lee, Seong Ho Choi - Annals of Surgery 2018 cited by 679
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
Authors: J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin, Hyun Cheol Chung, Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Светлана Проценко, Zev A. Wainberg, Marc Buyse, Karen Afenjar, Vincent Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, S. Khan‐Wasti, Sergio Santillana, Michael F. Press, Dennis J. Slamon - Journal of Clinical Oncology 2015 cited by 621
- Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Authors: Jung Yong Hong, Ji Yeong An, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung‐Mee Kim, Won Ki Kang, Seung Tae Kim - Translational Cancer Research 2020 cited by 93
- Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Authors: Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G. Mortimer, Justin I. Odegaard, Elizabeth A. Harrington, Ju-Young Lee, Taehyang Lee, Sung Yong Oh, Jung-Hun Kang, Jung Hoon Kim, Youjin Kim, Jun Ho Ji, Young Saing Kim, Kyoung Eun Lee, Jinchul Kim, Tae Sung Sohn, Ji Yeong An, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Jae J. Kim, Yang Won Min, Byung‐Hoon Min, Nayoung K. D. Kim, Sally Luke, Young Hwa Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung‐Mee Kim, Won Ki Kang - Cancer Discovery 2019 cited by 234
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Authors: Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park, Chung‐Pin Li, M. E. Scheulen, Saifuddin M. Kasubhai, Do‐Youn Oh, Yuan Liu, Suman Redhu, Klaudia Steplewski, Ngocdiep T. Le - European Journal of Cancer 2014 cited by 363
- Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer
Authors: Sujin Hyung, Jihoon Ko, You Jeong Heo, Steven M. Blum, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Won Ki Kang, Ho Yeong Lim, Samuel J. Klempner, Jeeyun Lee - Science Advances 2023 cited by 43
- Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Authors: Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Giuseppe Curigliano, Maitri Kalra, Do‐Youn Oh, Joon Oh Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura, Cristina Saura, Bob T Li, Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura - The Lancet Oncology 2024 cited by 101
- Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Authors: Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso, Maria Passhak, Hao‐Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stintzing, Kathryn Towns, Tae Won Kim, Kai‐Keen Shiu, Juan Cundom, Sumitra Ananda, A. A. Lebedinets, Rong Fu, Rishi Jain, David E. Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Élez, the LEAP-017 Investigators, Juan Cundom, Ezequiel Slutsky, Julieta Grasselli, Luis Fein, Luciana Bella Quero, Warren Joubert, Peter Gibbs, Timothy Price, Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross and 13 more - Journal of Clinical Oncology 2024 cited by 77
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Authors: Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung, Pamela Salman, Sang Cheul Oh, G. Bodoky, G. Kurteva, Constantin Volovăț, Vladimir Moiseyenko, В. А. Горбунова, Joon Oh Park, Akira Sawaki, Ilhan Celik, Heiko Götte, Helena Melezínková, Markus Moehler - The Lancet Oncology 2013 cited by 838
